321 related articles for article (PubMed ID: 11768626)
1. Neurochemical findings in the MPTP model of Parkinson's disease.
Schmidt N; Ferger B
J Neural Transm (Vienna); 2001; 108(11):1263-82. PubMed ID: 11768626
[TBL] [Abstract][Full Text] [Related]
2. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
[TBL] [Abstract][Full Text] [Related]
3. Protective role of SIRT5 against motor deficit and dopaminergic degeneration in MPTP-induced mice model of Parkinson's disease.
Liu L; Peritore C; Ginsberg J; Shih J; Arun S; Donmez G
Behav Brain Res; 2015 Mar; 281():215-21. PubMed ID: 25541039
[TBL] [Abstract][Full Text] [Related]
4. Loss of collapsin response mediator protein 4 suppresses dopaminergic neuron death in an 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
Tonouchi A; Nagai J; Togashi K; Goshima Y; Ohshima T
J Neurochem; 2016 Jun; 137(5):795-805. PubMed ID: 26991935
[TBL] [Abstract][Full Text] [Related]
5. Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease.
Duan W; Mattson MP
J Neurosci Res; 1999 Jul; 57(2):195-206. PubMed ID: 10398297
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of MPTP toxicity.
Przedborski S; Jackson-Lewis V
Mov Disord; 1998; 13 Suppl 1():35-8. PubMed ID: 9613716
[TBL] [Abstract][Full Text] [Related]
7. Modeling neurodegenerative diseases in vivo review.
von Bohlen Und Halbach O
Neurodegener Dis; 2005; 2(6):313-20. PubMed ID: 16909014
[TBL] [Abstract][Full Text] [Related]
8. Effects of different schedules of MPTP administration on dopaminergic neurodegeneration in mice.
Bezard E; Dovero S; Bioulac B; Gross C
Exp Neurol; 1997 Nov; 148(1):288-92. PubMed ID: 9398471
[TBL] [Abstract][Full Text] [Related]
9. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
10. Targeting reactive oxygen species, reactive nitrogen species and inflammation in MPTP neurotoxicity and Parkinson's disease.
Yokoyama H; Kuroiwa H; Yano R; Araki T
Neurol Sci; 2008 Oct; 29(5):293-301. PubMed ID: 18941931
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotection in Parkinson models varies with toxin administration protocol.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
[TBL] [Abstract][Full Text] [Related]
12. [Parkinsonism induced by MPTP as an experimental model of Parkinson disease: similarities and differences].
Luquin MR; Obeso JA; Herrero MT; Laguna J; Martínez-Lage JM
Neurologia; 1991 Oct; 6(8):287-94. PubMed ID: 1790005
[TBL] [Abstract][Full Text] [Related]
13. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation.
Delgado M; Ganea D
FASEB J; 2003 May; 17(8):944-6. PubMed ID: 12626429
[TBL] [Abstract][Full Text] [Related]
15. Lack of long-term changes in circadian, locomotor, and cognitive functions in acute and chronic MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse models of Parkinson's disease.
Fifel K; Dkhissi-Benyahya O; Cooper HM
Chronobiol Int; 2013 Jul; 30(6):741-55. PubMed ID: 23758587
[TBL] [Abstract][Full Text] [Related]
16. Preventive role of PD-1 on MPTP-induced dopamine depletion in mice.
Jung HW; Son HY; Jin GZ; Park YK
Cell Biochem Funct; 2010 Apr; 28(3):217-23. PubMed ID: 20186864
[TBL] [Abstract][Full Text] [Related]
17. Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) rat model of Parkinson's disease.
Prediger RD; Rial D; Medeiros R; Figueiredo CP; Doty RL; Takahashi RN
Ann N Y Acad Sci; 2009 Jul; 1170():629-36. PubMed ID: 19686204
[TBL] [Abstract][Full Text] [Related]
18. A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery.
Mounayar S; Boulet S; Tandé D; Jan C; Pessiglione M; Hirsch EC; Féger J; Savasta M; François C; Tremblay L
Brain; 2007 Nov; 130(Pt 11):2898-914. PubMed ID: 17855373
[TBL] [Abstract][Full Text] [Related]
19. The MPTP model of Parkinson's disease.
Smeyne RJ; Jackson-Lewis V
Brain Res Mol Brain Res; 2005 Mar; 134(1):57-66. PubMed ID: 15790530
[TBL] [Abstract][Full Text] [Related]
20. MPTP as a mitochondrial neurotoxic model of Parkinson's disease.
Przedborski S; Tieu K; Perier C; Vila M
J Bioenerg Biomembr; 2004 Aug; 36(4):375-9. PubMed ID: 15377875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]